-
Prostate: The ratio of lymphocytes to monocytes can predict clinically significant prostate cancer
Time of Update: 2021-10-10
Some previous studies have shown that the predictive role of systemic inflammation markers in clinically significant prostate cancer (CSPCs) is contradictory.
Some previous studies have shown that the predictive role of systemic inflammation markers in clinically significant prostate cancer (CSPCs) is contradictory.
-
Prostate: In transitional zone prostate cancer, which 18 F-DCFPyL PET diagnosis or MRI diagnosis is better?
Time of Update: 2021-10-10
To compare the performance of 18F-DCFPyL positron emission tomography (PET) and multi-parameter magnetic resonance imaging (mp-MRI) in the diagnosis of transition zone (TZ) prostate cancer (PCa).
-
2021CSCO: New exploration of immune adjuvant and neoadjuvant therapy in NSCLC
Time of Update: 2021-10-10
Non-small cell lung cancer ( NSCLC ) is one of the malignant tumors with the highest mortality rate. The tumor microenvironment in the early stage (stage I-III) of the disease can provide a favorable
-
Nat Med: Immune response to two and three doses of BNT162b2 mRNA vaccine in adults with solid tumors
Time of Update: 2021-10-10
The third dose of BNT162b2 vaccination is safe, can improve humoral immunity against SARS-CoV-2, and may have immunological benefits for cancer patients receiving active chemotherapy .
-
New immunotherapy is out!
Time of Update: 2021-10-10
Therefore, in this new study, the researchers tested the therapeutic effect of melanoma patients after NK cells were differentiated into memory-like NK cells .
-
Nat Commun: miRNA scoring system predicts the risk of colorectal cancer
Time of Update: 2021-10-10
Participant screening related flowchartParticipant screening related flowchartIn this study, the researchers derived a blood-based miRNA scoring system and evaluated its ability to predict the occurrence and development of CRC in adults aged 50-75 .
-
Front Oncol: The best type of surgery and adjuvant treatment for stage T1N0M0 lung large cell neuroendocrine carcinoma
Time of Update: 2021-10-10
Like lobectomy, regional lymph node dissection can also improve the survival rate of patients with tumors smaller than 2 cm.
Like lobectomy, regional lymph node dissection can also improve the survival rate of patients with tumors smaller than 2 cm.
-
Liver Cnacer: Real-world evaluation of the efficacy of Lenvatinib in the treatment of unresectable hepatocellular carcinoma (HCC)
Time of Update: 2021-10-10
Efficacy evaluationEfficacy evaluationWhen evaluating whether to meet the REFLECT eligibility criteria, there was no difference in ORR between the eligible and non-compliant cohorts (20.
When evaluating whether to meet the REFLECT eligibility criteria, there was no difference in ORR between the eligible and non-compliant cohorts (20.
-
Thoughts on the rational choice of chemotherapy drugs for breast cancer patients with high risk of recurrence
Time of Update: 2021-10-10
The original research Docetaxel has experienced the test of time to help patients with high risk of recurrence of breast cancer achieve their treatment goals and help hospitals improve the quality of medical care .
-
2021CSCO: Current and prospects of precision radiotherapy combined with immunotherapy for lung cancer
Time of Update: 2021-10-10
Progress in radiotherapy combined with immunotherapy for lung cancerProgress in radiotherapy combined with immunotherapy for lung cancerA phase II KEYNOTE-799 study evaluated the safety and efficacy of pembrolizumab combined with concurrent radiotherapy and chemotherapy in the treatment of stage III unresectable NSCLC .
-
After all the talents, the gluttonous event Sofantinib biliary tumor RWS clinical research project kick-off meeting was successfully held!
Time of Update: 2021-10-10
Professor Lu Jun of Shandong Provincial Hospital, Professor Du Futian from Weifang People’s Hospital, Professor Tian Hu from the First Affiliated Hospital of Shandong First Medical University, and Professor Cao Jingyu from Qingdao University Affiliated Hospital The experience of treatment and the main points discussed are summarized as follows: For unresectable locally advanced and metastatic biliary tract tumors, the efficacy of standard first-line chemotherapy is limited, and there are unmet clinical needs .
-
Prof. Zhiyan Liu: Interpretation of the updated pathological diagnosis of the 2021 edition of "CSCO Guidelines for Diagnosis and Treatment of Differentiated Thyroid Cancer", and explore the path to precision diagnosis and treatment of thyroid cancer
Time of Update: 2021-10-10
Therefore, in the "Chinese Standards for Diagnosis and Treatment of Thyroid Cancer (2018 Edition)", thyroid cancer molecular marker detection (such as BRAF V600E mutation, RAS mutation, RET/PTC rearrangement, etc.
-
WuXi Giant Nuo's Multiple Myeloma BCMA CAR-T Approved for Clinical, Market Potential Expands Strongly
Time of Update: 2021-10-10
Recommended reading: ASCO&EHA | Genxi Bio will announce the latest results of the BCMA/CD19 dual-targeting CAR-T cell therapy GC012F in the treatment of relapsed or refractory multiple myeloma.
-
100% prevention of lung cancer in mice, Su Da Liu Mi's team developed a nano-vaccine prepared from cancer cells
Time of Update: 2021-10-10
This method reassembles the whole cell components of cancer cells or tumor tissues into a nano-scale vaccine through PLGA nanoparticles, which is used for the prevention and immunotherapy of various types of cancer .
-
Front Oncol: Phase II single-arm study to evaluate the efficacy of apatinib combined with oral etoposide in the treatment of treated metastatic breast cancer
Time of Update: 2021-10-10
Combined chemotherapy as the first-line and second-line treatment of HER2-negative metastatic breast cancer significantly prolongs the median progression-free survival (PFS) .
Combined chemotherapy as the first-line and second-line treatment of HER2-negative metastatic breast cancer significantly prolongs the median progression-free survival (PFS) .
-
Front Oncol: Analyze the clinical features and prognosis of endometrial cancer based on the SEER database
Time of Update: 2021-10-10
In multivariate analysis, high tumor grade, non-endometrioid and sarcoma subtypes, liver and brain metastases, no surgery and no chemotherapy are unfavorable predictors of OS and CSS .
-
There are so many blisters on my body, and they are all rotten!
Time of Update: 2021-10-10
Pemphigus is just a more serious skin disease, and its pathogenesis is completely different from cancer .
Different clinical types of pemphigus cause different damage to patients .
-
NMPA accepts the application for Phase II clinical trial of Ebutuzumab and Pembrolizumab in the treatment of solid tumors
Time of Update: 2021-10-10
This phase II study is based on a number of According to the clinical research results of monoclonal antibodies in the treatment of tumors, we hope to speed up the development process of Ebutuximab and promote the approval of this innovative drug in China .
-
PD-1 antibody combined with chemotherapy can significantly prolong the survival time of patients with esophageal cancer
Time of Update: 2021-10-10
Recently, the team of Professor Ruihua Xu from the Cancer Center of Sun Yat-sen University led a report on JAMA entitled Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma-The ESCORT-1st Randomized Clinical Trial The article [3] found a new treatment method for patients with advanced esophageal squamous cell carcinoma .
-
Eur J Cancer: Long-term outcome of patients with advanced melanoma treated with pembrolizumab
Time of Update: 2021-10-10
This study aims to analyze the long-term prognosis of pembrolizumab in patients with early stable melanoma who have achieved complete or partial remission after treatment .
Most early (12 weeks) stable melanoma patients treated with pembrolizumab can later obtain partial or complete remission.
